Nephrol Dial Transplant (1999) 14: 2392-2406
© 1999 European Renal Association-European Dialysis and Transplant Association
Dyslipidaemia and the progression of renal disease in chronic renal failure patients
1 Service de Néphrologie, 2 Service de Biochimie A, and 3 INSERM U507, Hôpital Necker, Paris, France
Correspondence and offprint requests to: Ziad A. Massy MD, INSERM U 507, Necker Hospital, 161 rue de Sèvres, F-75730 Paris Cedex 15, France.
Background. Dyslipidaemia is common in patients with chronic renal failure (CRF), and there is increasing evidence to support the role of dyslipidaemia as a contributing factor in the progression of chronic renal disease. However, few prospective studies have been carried out which address the possible relationship between dyslipidaemia and the rate of progression of renal disease in patients with renal failure.
Methods. Between January 1985 and December 1997, we prospectively assessed the risk of CRF progression to dialysis in a cohort of 138 patients. Forty CRF patients reached end-stage renal disease (ESRD) and had to start supportive therapy during the follow-up period [group ESRD(+)]. The remaining 98 CRF patients served as controls [group ESRD(-)]. Potential clinical and laboratory risk factors for more rapid CRF decline to dialysis, including lipid abnormalities and baseline creatinine clearance were determined at the start of the follow-up period.
Results. Several significant differences were found in univariate analysis between the two groups of CRF, ESRD(+) and ESRD(-), namely a shorter follow-up period, a lower level of baseline creatinine clearance, a faster rate of creatinine clearance decline, a higher level of serum triglycerides, fibrinogen, total homocyst(e)ine and proteinuria, and a lower level of serum high-density lipoprotein in the ESRD(+) group than in the ESRD(-) group. However, by multivariate Cox analysis proteinuria [relative risk (95% confidence interval) 1.32 (1.16–1.50) for each g/day P=0.001], baseline creatinine clearance [0.53 (0.40–0.70) for each 10 ml/min, P=0.001] and chronic interstitial nephritis and hypertensive nephrosclerosis [0.38 (0.17–0.84) for presence, P=0.005] were the only significant risk factors for CRF progression to dialysis. Hypertriglyceridaemia and male gender were selected in the final model, but were of borderline significance.
Conclusions. These results suggest a limited role for dyslipidaemia in the progression of chronic renal disease to dialysis in CRF patients, in contrast with the powerful influence of proteinuria, baseline creatinine clearance and nephropathy type in predicting this progression.
Keywords: chronic renal failure; creatinine clearance; fibrinogen; homocyst(e)ine; lipids; lipoprotein(a)
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  P. Richtrova, K. Opatrny Jr, L. Vit, F. Sefrna, and R. Perlik The AN69 ST haemodialysis membrane under conditions of two different extracorporeal circuit rinse protocols a comparison of thrombogenicity parameters Nephrol. Dial. Transplant., October 1, 2007; 22(10): 2978 - 2984. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. C. Ozsoy, W. A. van der Steeg, J. J. P. Kastelein, L. Arisz, and M. G. Koopman Dyslipidaemia as predictor of progressive renal failure and the impact of treatment with atorvastatin Nephrol. Dial. Transplant., June 1, 2007; 22(6): 1578 - 1586. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Tovar and D. B. Schering Management of Dyslipidemia in Special Populations Journal of Pharmacy Practice, April 1, 2006; 19(2): 63 - 78. [Abstract] [PDF]
|
|
|
|
 |
|
 G. D'Amico Statins and Renal Diseases: From Primary Prevention to Renal Replacement Therapy. J. Am. Soc. Nephrol., April 1, 2006; 17(4_suppl_2): S148 - S152. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Boes, D. Fliser, E. Ritz, P. Konig, K. Lhotta, J. F.E. Mann, G. A. Muller, U. Neyer, W. Riegel, P. Riegler, et al. Apolipoprotein A-IV Predicts Progression of Chronic Kidney Disease: The Mild to Moderate Kidney Disease Study J. Am. Soc. Nephrol., February 1, 2006; 17(2): 528 - 536. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Phan, O. Ivanovski, T. Nguyen-Khoa, N. Mothu, J. Angulo, R. Westenfeld, M. Ketteler, N. Meert, J. Maizel, I. G. Nikolov, et al. Sevelamer Prevents Uremia-Enhanced Atherosclerosis Progression in Apolipoprotein E-Deficient Mice Circulation, November 1, 2005; 112(18): 2875 - 2882. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. R. Chade, A. Lerman, and L. O. Lerman Kidney in Early Atherosclerosis Hypertension, June 1, 2005; 45(6): 1042 - 1049. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Flack, R. Peters, T. Shafi, H. Alrefai, S. A. Nasser, and E. Crook Prevention of Hypertension and Its Complications: Theoretical Basis and Guidelines for Treatment J. Am. Soc. Nephrol., July 1, 2003; 14(90002): S92 - 98. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Gill, M. Tonelli, C. H. Mix, and B. J.G. Pereira The Change in Allograft Function among Long-Term Kidney Transplant Recipients J. Am. Soc. Nephrol., June 1, 2003; 14(6): 1636 - 1642. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. K. Salahudeen Halting progression of renal failure: consideration beyond angiotensin II inhibition Nephrol. Dial. Transplant., November 1, 2002; 17(11): 1871 - 1875. [Full Text] [PDF]
|
|